UDC 578.81: 579.62: 57.084.2
DOI: 10.36871/vet.zoo.bio.202310007
Authors
Nikolay V. Pimenov,
Moscow State Academy of Veterinary Medicine and Biotechnology – MVA by K. I. Skryabin”, Moscow, Russia
Alexey I. Laishevtsev,
Federal Scientific Center – All-Russian Research Institute of Experimental
Veterinary named after K. I. Skryabin and Ya. R. Kovalenko of
the Russian Academy of Sciences, Moscow, Russia
Abstract
The intensification of the production of livestock and poultry products determines the strengthening
of biological control and containment of the morbidity of animals, including birds, as well
as the spread of infections that determine sanitary and epizootic distress. Coli-salmonella infection
is widespread. By their antibiotic resistance, the microorganisms Escherichia coli and Salmonella
spp. they belong to a high and critical priority group, most of the existing antibiotics for which are
not active. To implement the tasks facing veterinary science and practice, formed by the global
problem of combating epizootics of escherichiosis and salmonellosis, ensuring sanitary well-being,
including products, a drug based on bacteriophages «EshriPhage» has been developed.
Commission tests of the etiotropic activity of the combined agent «EshriPhage» in vitro in the
spot test revealed a high level of epizootically significant isolates of coli-salmonella infection. Data
are presented that allow us to recommend the widespread introduction of EshriPhage into practice
and the further development of methods of epizootic control over bacterioses using bacteriophages.
Keywords
bacteriophages, escherihosis, salmonellosis, coli-salmonella infection, «EshriPhage», activity
